Oxurion (ex ThromboGenics)

BRU: OXUR | BE0003846632
Euronext Brussel

Mijn selectie

3,700 EUR -0,070 EUR (-1,86%)

21 januari 2019 11:44

Kosten order 3.000 EUR: 3,14 EUR 0,00 EUR
NOG 2 DAGEN: 500 euro GRATIS transacties bij DEGIRO

Vandaag

3,700

3,790

12 maanden

3,275

10,460

	Kosten order 3.000 EUR: 3,14 EUR 0,00 EUR
NOG 2 DAGEN: 500 euro GRATIS transacties bij DEGIRO » Vergelijk de kosten bij alle banken »

Laatste nieuws over Oxurion

Biotechaandelen kansrijk, maar niet voor doetjes

07 december 2018 - 18:19 | Tijd.be

De Belgische biotechsector pakte onlangs opnieuw uit met enkele successen. Sommige medicijnen staan voor een wereldwijde doorbraak. Welke bedrijven floreren, en bij welke zijn de risico’s nog torenhoo...
Tijd.be »

Oxurion NV Business Update - Q3 2018

19 oktober 2018 - 07:30 | ThromboGenics NV

Shareholders' Approval and Launch of Oxurion NV as new Company Name First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) First Patient enrolled in Phase 2...
Trivano.com »

Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)

20 september 2018 - 17:40 | ThromboGenics NV

Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics ), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced...
Trivano.com »

Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)

20 september 2018 - 07:30 | ThromboGenics NV

Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR), a biopharma company ( formerly known as ThromboGenics ) focused on developing treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease, announces that...
Trivano.com »

Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria

17 september 2018 - 17:40 | ThromboGenics NV

Leuven, Belgium, 17 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that...
Trivano.com »

Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Websit

10 september 2018 - 07:30 | ThromboGenics NV

Aandelennieuws in het kort

07 september 2018 - 16:30 | Bolero.be

Thrombogenics heeft nog 100 miljoen op de bank

06 september 2018 - 18:36 | Tijd.be

ThromboGenics Business Update - H1 2018

06 september 2018 - 17:40 | ThromboGenics NV

ThromboGenics becomes "Oxurion"

03 september 2018 - 17:40 | ThromboGenics NV

Euronext Brussel: Bekaert en Thrombogenics onderuit

20 juli 2018 - 17:42 | Tijd.be

ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)

19 juli 2018 - 17:40 | ThromboGenics NV

Aandelennieuws in het kort

27 juni 2018 - 16:30 | Bolero.be

Thrombogenics doopt zich om tot Oxurion

27 juni 2018 - 07:36 | Tijd.be

ThromboGenics Plans Name Change to "Oxurion"

27 juni 2018 - 07:30 | ThromboGenics NV

Oudere nieuwsberichten »